Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recording ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population: A Non-Interventional, Retrospective and Prospective Observational Study of Clinical Practice Data and Treatment Utilization Patterns in Routine Care

NCT07899463 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07899463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Recording ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population: A Non-Interventional, Retrospective and Prospective Observational Study of Clinical Practice Data and Treatment Utilization Patterns in Routine Care
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Observational
Overall status
Recruiting
Start date
May 13, 2025
Completion date
October 15, 2027
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (locally advanced or metastatic), esr1 gene mutation, hormon receptor positive breast cancer

Arms

As registered; 1 arm.

  • Metastatic HR+ Breast Cancer ESR1 Cohort

    Patients with metastatic HR-positive/HER2-negative breast cancer in Greece who have been tested for ESR1 mutations. Data collected include ESR1 mutation status (via NGS liquid biopsy), clinicopathological features, and treatment patterns in routine clinical practice. No changes to standard therapy are required, and data collection occurs only during routine clinical visits

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Prevalence of ESR1 mutations through study completion, an average of 1 year

    The proportion of patients with metastatic HR+/HER2- breast cancer in Greece who have detectable ESR1 mutations, determined by next-generation sequencing (NGS) of circulating tumor DNA (liquid biopsy) among all patients tested. Data are collected retrospectively and prospectively from routine clinical visits.

Lead sponsor's other trials

Hellenic Cooperative Oncology Group, most recent start first.

Similar trials

Same condition (Neoplasm Metastasis) and phase, most recent start first.